Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2021 08:00 ET | Source: Immutep Limited

Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer

Fast Track designation opens the potential for expedited development and review with the US FDAFast Track was granted based on the promising data package from Immutep, including from Immutep’s Phase...
December 29, 2020 16:54 ET | Source: Immutep Limited

Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor

Sydney, AUSTRALIA, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...
December 16, 2020 08:00 ET | Source: Immutep Limited

Immutep Upscales Efti Manufacturing

Sydney, AUSTRALIA, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
December 15, 2020 08:00 ET | Source: Immutep Limited

Immutep Operational Update

Efti clinical trial status updatesExcellent financial position following recent US$7.7 million warrant exercise, with cash runway extended beyond end of calendar year 2022 Sydney, AUSTRALIA, Dec. ...